Abstract Phosphorylation of serine 81 (pS81) in the N-terminal transactivation domain of the
androgen receptor (AR) has been linked to its transcriptional activation in prostate cancer …

Androgen receptor (AR) is the principal molecule in prostate cancer (PCa) etiology and
therapy. AR re‐activation still remains a major challenge during treatment of castration …

We previously reported that AR phosphorylation at serine 213 was associated with poor
outcome and may contribute to prostate cancer development and progression. This study …

Our previous findings indicated that androgen receptor (AR) phosphorylation at serine 81 is
stimulated by the mitotic cyclin-dependent kinase 1 (CDK1). In this report, we extended our …

Background The androgen receptor splice variant-7 (AR-V7) has been implicated in the
development of castration-resistant prostate cancer (CRPC) and resistance to abiraterone …

In clinical samples, the expression of androgen receptor (AR) and of AR splice variant 7 (AR‑
V7) is higher in castration‑resistant prostate cancer (CRPC) compared with that in hormone …

BACKGROUND. Liquid biopsies have demonstrated that the constitutively active androgen
receptor splice variant-7 (AR-V7) associates with reduced response and overall survival …

Importance A blood test to determine whether to treat patients with metastatic castration-
resistant prostate cancer (mCRPC) with an androgen receptor signaling (ARS) inhibitor or …

Background Despite increases in diagnostics and effective treatments, over 300,000 men
die from prostate cancer highlighting the need for specific and differentiating biomarkers. AR …

Purpose: Therapies targeting the androgen receptor (AR) have improved the outcome for
patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively …